Similar articles for PMID: 31643777

Year	Number of Results
2000	1
2007	1
2010	1
2011	1
2012	5
2013	8
2014	15
2015	12
2016	13
2017	10
2018	5
2019	11
2020	10
2021	7
2022	12
2023	6
2024	2

1

[No authors listed] [No authors listed] 2019 May 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 May 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643777 Free Books & Documents. Review.

2

Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.

Larrey D, D'Erasmo L, O'Brien S, Arca M; Italian Working Group on Lomitapide. Larrey D, et al. Liver Int. 2023 Feb;43(2):413-423. doi: 10.1111/liv.15497. Epub 2022 Dec 30. Liver Int. 2023. PMID: 36520008 Free PMC article. Clinical Trial.

3

Efficacy and Safety of Lomitapide in Hypercholesterolemia.

Liu X, Men P, Wang Y, Zhai S, Zhao Z, Liu G. Liu X, et al. Am J Cardiovasc Drugs. 2017 Aug;17(4):299-309. doi: 10.1007/s40256-017-0214-7. Am J Cardiovasc Drugs. 2017. PMID: 28255870 Review.

4

Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.

Kolovou G, Diakoumakou O, Kolovou V, Fountas E, Stratakis S, Zacharis E, Liberopoulos EN, Matsouka F, Tsoutsinos A, Mastorakou I, Katsikas T, Mavrogeni S, Hatzigeorgiou G. Kolovou G, et al. Eur J Prev Cardiol. 2020 Jan;27(2):157-165. doi: 10.1177/2047487319870007. Epub 2019 Aug 12. Eur J Prev Cardiol. 2020. PMID: 31403880

5

Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and β-oxidation.

Patel V, Joharapurkar A, Kshirsagar S, Patel M, Patel H, Savsani H, Jain M. Patel V, et al. Toxicol Appl Pharmacol. 2022 Jan 1;434:115825. doi: 10.1016/j.taap.2021.115825. Epub 2021 Dec 10. Toxicol Appl Pharmacol. 2022. PMID: 34902352

6

Case report: Therapy adherence, MTTP variants, and course of atheroma in two patients with HoFH on low-dose, long-term lomitapide therapy.

Kayikcioglu M, Ozkan HS, Yagmur B, Bayraktaroglu S, Vardarli AT. Kayikcioglu M, et al. Front Genet. 2023 Jan 4;13:1087089. doi: 10.3389/fgene.2022.1087089. eCollection 2022. Front Genet. 2023. PMID: 36685950 Free PMC article.

7

Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.

Blom DJ, Raal FJ, Santos RD, Marais AD. Blom DJ, et al. Curr Atheroscler Rep. 2019 Nov 19;21(12):48. doi: 10.1007/s11883-019-0809-3. Curr Atheroscler Rep. 2019. PMID: 31741187 Review.

8

Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.

Davis KA, Miyares MA. Davis KA, et al. Am J Health Syst Pharm. 2014 Jun 15;71(12):1001-8. doi: 10.2146/ajhp130592. Am J Health Syst Pharm. 2014. PMID: 24865757 Review.

9

Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.

Rizzo M. Rizzo M. IDrugs. 2010 Feb;13(2):103-11. IDrugs. 2010. PMID: 20127562 Review.

10

Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.

Khoury E, Brisson D, Roy N, Tremblay G, Gaudet D. Khoury E, et al. Expert Opin Drug Saf. 2019 May;18(5):403-414. doi: 10.1080/14740338.2019.1602606. Epub 2019 May 16. Expert Opin Drug Saf. 2019. PMID: 30945578 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year